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Informed consent, parental awareness, and
reasons for participating in a randomised
controlled study
Margriet van Stuijvenberg, Marja H Suur, Sandra de Vos, Gilbert C H Tjiang,
Ewout W Steyerberg, Gerarda Derksen-Lubsen, Henriëtte A Moll
Abstract
Background—The informed consent pro-
cedure plays a central role in randomised
controlled trials but has only been ex-
plored in a few studies on children.
Aim—To assess the quality of the in-
formed consent process in a paediatric
setting.
Methods—A questionnaire was sent to
parents who volunteered their child (230
children) for a randomised, double blind,
placebo controlled trial of ibuprofen syrup
to prevent recurrent febrile seizures.
Results—181 (79%) parents responded.
On average, 73% of parents were aware of
the major study characteristics. A few had
diYculty understanding the information
provided. Major factors in parents grant-
ing approval were the contribution to
clinical science (51%) and benefit to the
child (32%). Sociodemographic status did
not influence initial participation but west
European origin of the father was associ-
ated with willingness to participate in
future trials. 89% of participants felt posi-
tive about the informed consent proce-
dure; however, 25% stated that they felt
obliged to participate. Although their rea-
sons for granting approval and their
evaluation of the informed consent proce-
dure did not diVer, relatively more were
hesitant about participating in future.
Parents appreciated the investigator being
on call 24 hours a day (38%) and the extra
medical care and information provided
(37%) as advantages of participation. Dis-
advantages were mainly the time consum-
ing aspects and the work involved (23%).
Conclusions—Parents’ understanding of
trial characteristics might be improved by
designing less diYcult informed consent
forms and by the investigator giving extra
attention and information to non-west
European parents. Adequate measures
should be taken to avoid parents feeling
obliged to participate, rather than giving
true informed consent.
(Arch Dis Child 1998;79:120–125)
Keywords: informed consent; randomised controlled
trials; ibuprofen; febrile convulsions
Informed consent issues relating to clinical
research involving children are increasingly
attracting professional interest.1–3 The in-
formed consent procedure plays a central role
in randomised controlled trials. However,
studies of the issues in clinical trials involving
children are limited. Understanding parental
comprehension and their reasons for approval
might lead to changes in the procedure that
could enhance its quality. Based on the
information provided, parents decide whether
or not to permit their child to participate;
therefore, we should aim to provide adequate
information about the study. Understanding
how parents perceive the diVerent aspects of
research procedures could lead to improved
quality of comfort for children and parents
participating in future studies. In addition,
compliance might increase and withdrawal
might be reduced, factors that would benefit
the study itself.
We assessed how parents who had given
informed consent for their children to partici-
pate in a randomised controlled trial of ibupro-
fen to prevent recurrent febrile seizures evalu-
ated the information presented. We
determined their sociodemographic status,
their awareness of major study characteristics,
their reasons for granting approval, their
perception of the informed consent procedure,
the perceived advantages and disadvantages of
participation, and their willingness to partici-
pate in future studies.
Patients and methods
PATIENTS
The study population consisted of parents or
guardians who had volunteered their child for a
randomised, double blind, placebo controlled
trial of ibuprofen to prevent febrile seizure
recurrences.4 All children were between 1 and 4
years old, with a recognised risk of febrile
seizure recurrence, and parents were Dutch or
English speaking. Each child had visited the
emergency room of the Sophia Children’s
Hospital in Rotterdam or the Juliana Chil-
dren’s Hospital in Den Haag because of a
febrile seizure. Children (n = 230) were in-
cluded in the trial between 1 October 1994 and
1 April 1996 and followed up until 1 October
1996. The trial procedures complied with
Dutch national legislation and international
guidelines.5 The trial protocol was approved by
the institutional review boards of the hospitals
involved.
INFORMED CONSENT PROCEDURE
Two weeks after their febrile seizure, each child
visited the special febrile seizure outpatients’
clinic. If children were eligible, the trial was
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explained verbally, after which the informed
consent form was presented.Matters discussed
included the rationale, design and procedures,
medication, risks, possible negative side effects,
and parents’ freedom to withdraw the child at
any time. If the parents requested, they
received a copy of the signed informed consent
form to take home. If they needed time to con-
sider the invitation to participate, a new
appointment was made. They were asked to
telephone the investigator at fever onset (24
hours a day), to start promptly and to continue
administering the study medication every six
hours until the child had been afebrile for 24
hours, and to notify the investigator in the
event of seizure recurrence. If no fever had
been reported, the investigator contacted
parents every three months. At every contact
parents were reminded of the study details.
METHODS
We compiled a questionnaire consisting of
structured and semistructured questions about
the sociodemographic status of the parents,
how they evaluated the information presented
about the study, their awareness of major study
characteristics, their reason for granting ap-
proval, their perception of the informed
consent procedure, the advantages and disad-
vantages of participation, and their willingness
to participate in future studies.6 7
In May 1996, we decided to send the
questionnaire to the parents of the children
whose participation in the trial ended before
April 1996. In May 1997, the remaining
parents were sent questionnaires. All parents
were unaware of the results of the trial and the
treatment to which their child had been
randomly allocated. Two investigators who had
not yet been involved in the trial sent a letter of
introduction to parents to introduce the ques-
tionnaire and request their consent. The ques-
tionnaire and written instructions were sent
two weeks later. The parents of 15 (7%)
children were not contacted because: (1) they
were lost to follow up during the trial (n = 5),
(2) they were lost to follow up after completion
of the trial (n = 8), or (3) they had participated
in another febrile seizure research project
(n = 2). Of the remaining 215 (93%) eligible
parents, 32 did not respond to our announce-
ment and request, without giving a reason.Two
questionnaires were returned incomplete.
Thus, the study population consisted of the
parents of 181 (79%) children.
STATISTICAL ANALYSIS
Completed questionnaires were coded and
analysed.8 The answers were categorised into
groups. Sociodemographic details were defined
in categories.9 10 The association between
sociodemographic data and the answers was
studied using logistic regression. The signifi-
cance level was set at 0.05. Multivariable
analysis was done with backward regression
(p = 0.10). Odds ratios (OR) are given with
their 95% confidence interval (CI).
Results
BASELINE CHARACTERISTICS
The study population consisted of 181 mothers
and 155 fathers. There were 26 (14%) single
parent families. Table 1 summarises the socio-
demographic baseline characteristics.
COMPREHENSIBILITY OF INFORMATION
Parents of 176 children (97%) evaluated the
verbal information as easy to understand and
four (2%) thought that it was diYcult to
understand. The general information leaflet
about fever and febrile seizures and the
informed consent form were evaluated as easy
to understand by parents of 171 (95%)
children and as diYcult to understand by seven
(4%), including four parents who evaluated the
verbal information as diYcult. All seven moth-
ers were of a non-West European origin and
the parents of six children were of unskilled
occupation and limited education level.
AWARENESS OF SIX MAJOR TRIAL
CHARACTERISTICS
We asked parents to describe in their own
words the aim of the trial. We used a multiple
choice question to determine why they thought
they had to sign the informed consent form.We
assessed the knowledge of the other four trial
characteristics (table 2).
Table 1 Sociodemographic baseline characteristics
Mothers (n = 181) Fathers (n = 155)
Median age in years (25th–75th percentiles) 32.6 (29.0–37.0) 35.6 (31.6–39.5)
West European origin 135 (75%) 118 (77%)
Occupation
Unknown 2 (1%) 4 (3%)
Low
Elementary profession 5 (3%) 3 (2%)
Lower profession 21 (12%) 36 (23%)
No profession 71 (39%) 2 (1%)
High
Intermediate profession 59 (33%) 73 (47%)
Higher profession 20 (11%) 33 (21%)
Scientific profession 3 (2%) 4 (3%)
Education
Unknown 2 (1%) 3 (2%)
Low
Elementary school 23 (13%) 13 (8%)
Lower general secondary education 21 (12%) 13 (8%)
Vocational training (lower level) 31 (17%) 34 (22%)
High
Higher general secondary education/
pre-university education 23 (13%) 17 (11%)
Vocational training (intermediate level) 46 (25%) 31 (20%)
Vocational training (higher level) 29 (16%) 34 (22%)
University education 6 (3%) 10 (6%)
Table 2 Awareness of six major trial characteristics
Number (%) of
parents (n = 181)
Aim of the study
Assessment of eYcacy of antipyretic treatment or ibuprofen to prevent
febrile seizures 95 (53%)
Increase understanding of febrile seizures 63 (35%)
Test or invent a new drug in children 17 (9%)
Study of ibuprofen to provoke febrile seizures 3 (2%)
Do not remember 3 (2%)
Reason for signing the informed consent form
Indication of being completely informed and approval of participation 136 (75%)
Protectional rights
For the investigator 14 (8%)
For themselves and their child 12 (7%)
For both 1 (1%)
Do not remember why they had signed it 16 (9%)
Do not remember that they had signed it 2 (1%)
Possible negative side eVects 73 (40%)
50% chance of being assigned a placebo 160 (88%)
Random allocation procedure 91 (50%)
Possibility of withdrawing 165 (91%)
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Of the three parents who did not remember
the aim of the trial, two were not aware why
they had signed the informed consent form.
Nonetheless, the two parents who did not
remember that they had signed it understood
the aim of the trial.
As expected, all parents who knew about the
random allocation procedure (n = 91) were
also aware of the 50% chance for the child to be
assigned a placebo.
Eighty two (45%) of the parents were aware
of five to six major trial characteristics. This
high level of awareness was associated with two
parent family (OR = 3.2; CI, 1.2 to 8.4;
p = 0.02), high education level of the mother
(OR = 2.3; CI, 1.3 to 5.0; p = 0.01), and West
European origin of the mother (OR = 8.6; CI,
3.4 to 21.7; p < 0.01) and father (OR = 6.3;
CI, 2.4 to 16.7; p < 0.01). In the multivariate
model, West European origin of the parents
was retained.
None of the parents who evaluated either the
verbal or the written information as diYcult
(n = 7) could remember more than three of the
six major trial characteristics. They had most
diYculty with remembering the aim of the
trial, the reason for signing the informed
consent form, and the random allocation
procedure.
MAJOR REASONS FOR GRANTING APPROVAL
The major reasons for parents granting ap-
proval are shown in table 3. The largest group
consisted of parents whose major reason for
participation was to contribute to clinical
science (51%).We asked parents if they had felt
obliged to participate in the trial; 45 (25%)
parents answered aYrmatively. We compared
the reasons for approval of those parents who
had felt obliged to participate with the reasons
of those who had not; no significant diVerence
was found.
PERCEPTION OF THE INFORMED CONSENT
PROCEDURE
Table 4 shows how parents perceived the
informed consent procedure when they at-
tended the febrile seizure outpatients clinic.We
asked them how they had felt about our invita-
tion to volunteer their child for a clinical
research project. Most felt positive (n = 165;
91%) and thought that it was eYciently
planned or they felt that the time was conven-
ient for them to consider the invitation. Five
parents felt positive but had objections: either
they had been taken by surprise (n = 2) or they
felt the invitation was an extra problem to think
about (n = 3). Four (2%) parents felt negative
because they felt that they had been taken by
surprise; two of them felt obliged to participate.
Their major reason for approval was to
contribute to clinical science.
Forty two of the 45 parents who felt obliged
to participate (93%) felt positive about the
invitation.
Of the seven parents who thought that they
did not have suYcient time to decide whether
to participate, four felt positive and three felt
negative about the invitation, because they felt
taken by surprise. There were also seven
parents who considered that they had not
received suYcient explanation; six of them had
received suYcient time. Of the 13 parents who
had either not received suYcient time or expla-
nation, four felt obliged to participate. Their
reasons for approval were: contribution to
clinical science (n = 3) and benefit of their own
child (n = 1).
PERCEPTION OF PARTICIPATION
The major advantages and disadvantages of
participation are shown in table 5. The parents
answered this question in their own words. One
hundred and fifty six (86%) mentioned an
advantage and 65 (36%) mentioned a disad-
vantage of participation.
All parents were asked whether they were
concerned about possible negative side eVects
of antipyretic drugs for their child in general:
75 (41%) parents were concerned and 105
(58%) were not.
Table 3 Major reasons for approval versus feeling obliged to participate
Felt obliged to participate
No (n = 136) Yes (n = 45)
Contribution to clinical science (n = 92; 51%) 67 (49%) 25 (56%)
Benefit for their own child (n = 58; 32%) 46 (34%) 12 (27%)
Benefit for other children in future (n = 5; 3%) 4 (3%) 1 (2%)
Benefit for the parent (n = 6; 3%) 5 (4%) 1 (2%)
Give something in return for the care of their child (n = 12; 7%) 9 (7%) 3 (7%)
The doctor asked (n = 6; 3%) 4 (3%) 2 (4%)
No major reason (n = 2; 1%) 1 (1%) 1 (2%)
Table 4 Perception of the informed consent procedure
Felt obliged to participate
No (n = 136) Yes (n = 45)
Evaluation of invitation to participate
Negative (n = 4; 2%) 2 (1%) 2 (4%)
Positive (n = 165; 91%) 123 (90%) 42 (93%)
Positive, but objections (n = 5; 3%) 4 (3%) 1 (2%)
No evaluation (n = 7; 4%) 7 (5%) 0 (0%)
SuYcient time to decide
Yes (n = 174; 96%) 132 (97%) 42 (93%)
No (n = 7; 4%) 4 (3%) 3 (7%)
SuYcient explanation
Yes (n = 174; 96%) 131 (96%) 43 (96%)
No (n = 7; 4%) 5 (4%) 2 (4%)
Table 5 Advantages and disadvantages of participation
Number (%) of
parents (n = 181)
Advantages
Investigator on call 24 hours a day 68 (38%)
Extra medical care and information 66 (37%)
The possible eYcacy of the study medication 22 (12%)
No advantages 25 (14%)
Disadvantages
Temperature measurements and administering of study medication during
a fever episode 21 (12%)
Hospital visits at fever onset 10 (6%)
Time consuming aspect and work involved in general 10 (6%)
The possible ineYcacy of the study medication 4 (2%)
Other
Bad taste of the study medication 3 (2%)
Possible side eVects 6 (3%)
Not allowed to administer paracetamol 4 (2%)
Uncertainty about administering placebo or ibuprofen 6 (3%)
Entering the medical circuit 1 (1%)
No disadvantages 116 (64%)
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WILLINGNESS TO PARTICIPATE IN FUTURE
STUDIES
The results of the questions about the willing-
ness and reasons for future participation in
another study resembling our clinical trial are
shown in table 6. More than half of the parents
(n = 109; 60%) were willing to participate in a
similar future study. We found willingness to
participate again associated with West Euro-
pean origin of the father (OR = 2.0; CI, 0.9 to
4.2; p = 0.08), although the results were not
significant. The level of awareness of major trial
characteristics did not play a role.
We compared the reasons for being prepared
to participate in future trials to the initial
reasons for approval. Of the 44 parents who
were willing to contribute to clinical science, 32
(73%) had initially given this as the main
reason for approval. The reason for participat-
ing in future studies being the benefit of their
own child or other children (n = 32) was men-
tioned initially by 14 (44%) of these parents .
We defined four groups of parents (table 7):
(1) those who mentioned an advantage only
(n = 96), and had the highest percentage
willing to participate again (68%); (2) those
who mentioned both advantages and disadvan-
tages (n = 60), and had a slightly lower
percentage willing to participate again (58%);
(3) those who did not mention either an
advantage or a disadvantage (n = 20), and had
an even lower percentage (35%) willing to par-
ticipate again; and (4) parents who mentioned
a disadvantage only (n = 5), and had the high-
est percentage not willing to participate again,
although the number was small (n = 2). The
third group included the highest percentage
not knowing whether they would participate.
Table 8 shows an association between
willingness to participate in a future study and
feeling obliged to participate. Parents who did
not know whether they would participate
included a relatively higher number who had
felt obliged initially (n = 21; 36%), compared
with the parents who were certain about
whether to participate, 19% and 21%, respec-
tively (OR = 2.3; CI, 1.2 to 4.7; p = 0.02).
Discussion
The levels of education and occupation of the
responding parents are similar to the Dutch
national data for 1996 on educational and
occupation levels.11 Similar studies have shown
varying results: parents who permit their child
to participate in clinical research can have the
same, a higher, or a lower education or occupa-
tion level than those who do not.1 2 12 There is a
relatively open and easily accessible health care
system in the Netherlands, which makes selec-
tion bias unlikely with respect to socio-
economic status.
The informed consent form might have been
diYcult to read.13 However, only a few parents
evaluated the written information as diYcult to
understand. In addition, verbal information
was evaluated as diYcult by a few parents. In
general, studies concerning the level of diY-
culty of informed consent forms conclude that
investigators should keep the form simple, use
short words and sentences, and avoid medical
jargon.14–17 Although language diYculty was an
exclusion criterion for the febrile seizures trial,
the linguistic usage was clearly too diYcult for
non-West European parents. The problem
might, at least in part, be resolved by using
informed consent forms in native languages.
The degree of awareness of the major trial
characteristics was generally suYcient: 45% of
parents were aware of five or six trial character-
istics. A high level of awareness was associated
with West European parental origin. Parents
who had mentioned diYculties understanding
the information provided also had diYculties
recalling the trial characteristics. In general,
parents understood the details of the trial,
despite the diYcult informed consent form.
Detailed and repeated explanation of the study
by the investigator might have played a positive
role.18 In non-West European parents, cultural
diVerences regarding health might also have
contributed to diYculties in understanding the
information provided.
Half the participants (53%) correctly ex-
pressed the aim of the trial. In adult trials, these
percentages vary between 60% and 87%,18–20
compared with 97% in a paediatric study.21 In
our study, we asked parents to describe the aim
of the study in their own words. This is a more
diYcult task, which might explain our relatively
low percentage. In future, we will ask parents to
describe the aim of the trial in their own words
at the time that they are invited to participate
and informed consent is discussed.
Table 6 Willingness and reasons for participation in a similar future study
Number (%) of parents
(n = 181)
Willing to participate 109 (60%)
Contribution to clinical science 44 (24%)
Benefit for their own child and other children 32 (18%)
Extra medical care and support 19 (10%)
No motive 14 (8%)
Not willing to participate 14 (8%)
Time and work involved 7 (4%)
No benefit for their own child 4 (2%)
Uncertainty about receiving placebo or active treatment 1 (1%)
No reason 2 (1%)
Do not know 58 (32%)
It depends on the study 4 (2%)
Reluctance to be involved with the hospital 1 (1%)
No reason 53 (29%)
Table 7 Willingness to participate in a similar future study versus advantages and
disadvantages of participation
Willing to participate in a similar future study
No (n = 14) Yes (n = 109)
Do not know
(n = 58)
Only advantages (n = 96) 3 (3%) 65 (68%) 28 (29%)
Advantages and disadvantages (n = 60) 7 (12%) 35 (58%) 18 (30%)
Neither advantages nor disadvantages
(n = 20) 2 (10%) 7 (35%) 11 (55%)
Only disadvantages (n = 5) 2 (40%) 2 (40%) 1 (20%)
Table 8 Willingness to participate in a similar future study versus initially feeling obliged
to participate
Felt initially obliged to participate
Willing to participate in a similar future study
No (n = 14) Yes (n = 109) Do not know (n = 58)
No (n = 136; 75%) 11 (79%) 88 (81%) 37 (64%)
Yes (n = 45; 25%) 3 (21%) 21 (19%) 21 (36%)
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In our study, all parents were aware that they
had participated in a clinical trial, although we
are doubtful about the two parents who knew
neither the aim of the study nor the reason for
signing the informed consent form. Studies
involving adult participants show a similar
awareness of between 86% and 98%.18 19
A signed informed consent form is a legal
requirement instituted for the protection of
participants. In our study, 75% of participants
knew why they had to sign the informed
consent form, which indicates a minor inad-
equacy in this respect. Another paediatric
study has shown that only 19% knew the
reason for signing; a larger group thought it was
to protect the doctors.21
The information about possible negative side
eVects was recalled by 40% which, in our opin-
ion, is low. Only a few parents mentioned
negative side eVects as a disadvantage of
participation and most claimed not to be con-
cerned about the side eVects of antipyretic
treatment in general. A varying percentage
(between 4% and 78%) has been shown in
studies in which adult participants were
involved; the higher percentages in oncology
trials compared with antihypertensive treat-
ment studies.18 20 22 The low recall in our study
is unlikely to have resulted from the way in
which we presented the information, because
the informed consent form describes all
negative side eVects reported, in a similar way
to the standard instruction leaflet for ibuprofen
syrup. Low recall might be explained by the
relative safety of ibuprofen and the fact that
assessment of drug safety was not the aim of
the trial.
Similarly, parents were also highly aware
(88%) of their child’s chance of receiving
placebo. Only 3% of parents mentioned this as
a major disadvantage of participation; for one
parent this was the reason for refusing to
participate in a future trial. In a paediatric
study of paracetamol, over half of the parents
refused to participate, mainly because of a
reluctance to risk being assigned a placebo.12 In
adult studies, the awareness of this risk is much
lower (56%) than in our study, which might, at
least in part, be explained by parental fear of a
recurrent febrile seizure.20 23 24
The random assignment procedure was
recalled by half of the parents. All parents who
knew about the random allocation procedure
were also aware of the 50% chance of being
assigned a placebo. In adult clinical trial
participants, this issue plays a role as well;
awareness of the random assignment proce-
dure varies between 47% and 75%.18–20 The
fact that the parents trust the investigator
implicitly in knowing what is best for their child
might explain this lower awareness level.2 In
addition, “random assignment” is a theoretical
concept, which is diYcult to explain. A
concrete example of drawing lots would be
better.
The possibility of withdrawing from partici-
pation at any time was remembered by most
parents (91%). One paediatric study21 showed
a much lower value (45%) compared with
44–87% in adult studies.18 19 22
Parents can be encouraged to participate in
clinical research. This is best illustrated by the
relatively high participation rate (84%) among
the patients who were eligible for our febrile
seizures trial4 compared with other febrile
seizure studies (50–99%).25–29 Secondly, the
response rate (79%) to our questionnaire study
was high compared to other paediatric in-
formed consent questionnaire studies
(59–70%).1 2 The high participation rate in our
trial might be explained by the setting of the
initial invitation to participate: a special out-
patients’ clinic for febrile seizures in a quiet
environment with suYcient time and attention.
In our study, 32% of parents stated that they
participated for the benefit of their own child.
This was a consistent motive, although not as
frequently expressed as the willingness to con-
tribute to clinical science (51%), which was the
main and most consistent reason for parents to
participate. We found that a high percentage of
parents in our study (60%) were willing to par-
ticipate again in the future. This was associated
with a West European origin of the father.
Other studies have shown that a substantial
number of patients are willing to participate,
even without being adequately informed about
the benefits and risks,2 3 21 22 and despite the
fact that it will cost them time and eVort.1 22 30
A more reserved attitude towards participation
of their child in clinical research was found in
one of these studies: 21% of the parents were
prepared to participate for the benefit of other
children, contribution to clinical science, and
confidence in physicians, while 74% would
refuse because of the risk of side eVects and
unproved eYcacy of the trial medication.2 The
attitude on the part of parents might have been
influenced negatively by the study design; the
investigators asked only hypothetical questions
instead of questions addressed to parents who
were actual participants. Obviously, one’s own
benefit is a main reason for participation, but
the benefit for future patients and the contribu-
tion to medical science prevail.1 2 19 30 We feel
this generally positive attitude towards clinical
research is positive and promising for future
studies. Extra attention should be given to
non-West European trial participants to in-
crease their willingness to participate.
We found a substantial number of parents
mentioning the time consuming aspect and the
work involved as a major disadvantage of
participation; a small group of parents (4%)
thought that they would refuse to participate in
a similar study for this reason. Furthermore,
participating parents who did not mention an
advantage were more hesitant to agree to
participate in a similar future study. If they
mentioned an advantage of participation they
were prepared to put up with disadvantages;
disadvantages play a minor role in future
participation.
We were not sure how parents would
experience being asked to participate during
their appointment at the special febrile seizure
outpatients’ clinic. We found that 25% of the
parents felt obliged to participate. This might
be related to the feeling of being dependent on
the investigator or the hospital. A relatively
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large number of those hesitant to participate in
a future study were among the parents who felt
obliged to participate. However, of the parents
who felt obliged to participate only two (4%)
approved because the doctor asked. Other
explanations might be that they felt forced to
participate because of their responsibility,
either owing to the rather frightening disease of
their own child, other children, or scientific
development in general. We showed that
parents who felt obliged to participate have
similar major reasons for granting approval and
a similar evaluation of the informed consent
procedure compared with parents who do not
feel obliged, indicating that they do not diVer
as much as one might assume. However, we
consider the fact that parents felt obliged to
participate as a failure of our informed consent
procedure, because feeling obliged to partici-
pate might exclude giving truly informed con-
sent. The involvement of a third party (such as
a research nurse), to provide parents with
information and to invite them to participate,
might be advisable.18 We oVered parents some
time for reflection, if they so requested; a com-
pulsory time period for parents to consider the
matter might also be implemented to improve
the procedure.
One of the limitations of this study is the
number of parents (14%) who did not respond
to the questionnaire. We do not know their
reasons, but it might be that they would evalu-
ate our trial less positively than those who were
willing to fill in the questionnaire. Thus, we
might have overestimated the generally positive
evaluation of the trial. Furthermore, the ques-
tionnaire that we used has not been validated
completely. The questions concerning socio-
demographic status, awareness of major study
characteristics, and advantages and disadvan-
tages of participation were formulated using
the Lynn method,6 which has been used in
other studies.1 20 30 We tried to minimise
implied value judgments in our questions, but
the diYculty encountered in all questionnaire
studies regarding participants’ tendency to give
socially desirable answers inevitably played a
role in our study. However, we think that the
results of our study are relevant to comparable
study populations with respect to the subjects
(children), the design (randomised, placebo
controlled), the disease (good prognosis but
distressing), and the treatment (safe and not
invasive).
CONCLUSION
Parents’ understanding of trial characteristics
might be improved by a less diYcult informed
consent form and by the investigator giving
extra attention and information to non-West
European parents regarding linguistic prob-
lems and paying more attention to cultural dif-
ferences, even in the absence of language diY-
culties.
The contribution to clinical science and the
benefit of the child are major factors in the
recruitment of participants. With respect to
willingness to participate, advantages of par-
ticipation are more important than disadvan-
tages. Sociodemographic status does not influ-
ence initial participation, but the origin of the
father might determine his willingness to
participate in future trials. Some parents feel
obliged to participate; therefore, adequate
measures should be taken to ensure that
informed consent is genuine.
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